Search

Background Breast cancer subtype classification according to hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) using immunohistochemistry is the standard practice for therapeutic decision making. Objective To design future studies information on characteristics and survival of each subtype is essential. Method We conducted a retrospective study to analyze clinical and pathologic features as well as survival data according to breast cancer immunohistochemistry subtype. Results There were 211 women with a RH(+)/HER2(-) breast cancer subtype, 53 HR(+)/HER2(+), 16 HER2(+) and 23 HR(-)/HER2(-), with a median overall survival in months of 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) and 26 (11-78), respectively, for a 3.7 hazard ratio of death (95% Confidence Interval [CI]: 1.3-10.3) for the triple negative group as compared to the HR(+)/HER2(-) group (p = 0.01). Conclusions HR positive subtypes by immunohistochemistry where most frequent and showed a greater overall survival compared to the triple negative subtype.

espanolAntecedentes: La clasificacion del cancer de mama en subtipos mediante la expresion de receptores hormonales (RH) y del receptor 2 del factor de crecimiento epidermico humano (HER2) por inmunohistoquimica (IHQ) es una practica estandar para la toma de decisiones terapeuticas. Objetivo: Conocer las caracteristicas y supervivencia de cada subtipo de pacientes, que es indispensable para poder disenar futuros estudios. Metodo: Realizamos un estudio retrospectivo evaluando las caracteristicas clinicopatologicas y la supervivencia por subtipo mediante IHQ en mujeres con cancer de mama. Resultados: 211 mujeres con cancer de mama RH(+)/HER2(–), 53 con RH(+)/HER2(+), 16 con HER2(+) y 23 con RH(–)/HER2(–), con una mediana de supervivencia global en meses de 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) y 26 (11-78), respectivamente, para un cociente de riesgo (HR por sus siglas en ingles, Hazard Ratio): 3.7 (IC 95%: 1.3-10.3) en el grupo triple negativo comparado con RH(+)/HER2(–) (p = 0.01). Conclusion: Los subtipos con RH positivos por IHQ son los mas frecuentes y este grupo de pacientes tienen una mejor supervivencia global comparada con las pacientes triple negativo. EnglishBackground: Breast cancer subtype classification according to hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) using immunohistochemistry is the standard practice for therapeutic decision making. Objective: To design future studies information on characteristics and survival of each subtype is essential. Method: We conducted a retrospective study to analyze clinical and pathologic features as well as survival data according to breast cancer immunohistochemistry subtype. Results: There were 211 women with a RH(+)/HER2(–) breast cancer subtype, 53 HR(+)/HER2(+), 16 HER2(+) and 23 HR(–)/HER2(–), with a median overall survival in months of 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) and 26 (11-78), respectively, for a 3.7 hazard ratio of death (95% Confidence Interval [CI]: 1.3-10.3) for the triple negative group as compared to the HR(+)/HER2(–) group (p = 0.01). Conclusions: HR positive subtypes by immunohistochemistry where most frequent and showed a greater overall survival compared to the triple negative subtype.